Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

To determine the maximum tolerated dose of intravenous estramustine phosphate combined with Taxol. To estimate the complete and partial response rates to treatments with intravenous estramustine phosphate combined with Taxol in the treatment of hormone-refractory adenocarcinoma of the prostate. To determine the qualitative and quantitative toxicity of the combination of intravenous estramustine phosphate and Taxol.